Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:732-733 (5 April), doi:10.1136/bmj.39490.692627.80
Should be individually tailored but may not be necessary for all
| The first 150 words of the full text of this article appear below. |
More than three quarters of children with cancer survive into adulthood, but cure is not the end of their journey. At least 60% have substantial morbidities as a result of their curative treatment. Most adults who survive cancer are discharged from active follow-up at five years, but historically children have been followed up for life; this is becoming unsustainable. A review published in the BMJ more than five years ago explored strategies for follow-up of children who have survived cancer.1 Has anything changed since then?
Two large epidemiological studies—one in the United States and the other in the United Kingdom—have since been published.2 3 More than 10 000 survivors in 26 centres participated in the US study, which found that 62% of survivors have some late effects of treatment (common terminology criteria for adverse events (version 3) grade 1-5), with 27% having severe or life threatening conditions (grade 3-5).4 Data from
Meriel Jenney, consultant paediatric oncologist1, Gill Levitt, consultant in paediatric oncology and late effects2
1 Childrens Hospital for Wales, Cardiff CF14 4XW, 2 Great Ormond Street Hospital, London WC1N 3JH
meriel.jenney@cardiffandvale.wales.nhs.uk
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+